| 标题 |
65MO Neoadjuvant HLX11 versus European Union (EU)-sourced pertuzumab in human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-negative early or locally advanced, breast cancer (BC): A double-blind, randomised phase III equivalence study |
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of Oncology 作者:Q. Liu; Y. Yang; J. Zhang; J. Zhu; D. Song; et al 出版日期:2025 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)